Health Source: TSLP Monoclonal Antibody Approved for Clinical Trials for New Indications

Health Ocean announcement, the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the addition of "Chronic Sinusitis with Nasal Polyps" indication to the TSLP monoclonal antibody of the company. As of the date of this announcement, the accumulated research and development investment in this product is approximately RMB 82,882.4 million.